Clinical Trials Directory
We are doing this study to find out if an investigational drug called HM43239 (the study drug) is a safe and effective option for people who have AML that came back after remission or did not respond to standard treatments. We also want to find out what dose of the study drug works best for most patients.
We are doing this study to find the most effective, safe dose of an experimental drug called amivantamab (the study drug) when it is given in combination with lazertinib and chemotherapy. We want to know if this study drug regimen is effective for people with non-small cell lung cancer (NSCLC) who have a specific mutation in the EGFR (epidermal growth factor receptor) gene.
If you decide to participate in this study, you will have a screening visit to see if you meet the criteria to be included in this study. If you are eligible, you will proceed to the study drug period. During this period, you will:
- Take the study drug tablets by mouth at about the same time each morning and within 30 minutes of finishing your breakfast for the first 15 days
- After the first 15 days, continue to take the study drug by mouth at approximately the same time every day, within 30 minutes of finishing a meal (breakfast, lunch, or dinner) of your choice
- Blood draws
- Imaging tests (CT, PET/CT and MRI)
- ECG
We are doing this study to find out if an experimental drug called STM-416 (the study drug) is a safe and effective option for patients with a history of high grade, non-muscle invasive bladder cancer (cancer only within the bladder) whose disease has returned and who require an operation to remove cancer from the bladder.
We are doing this study to find the most effective, safe dose of an experimental drug called talquetamab (the study drug) for people with relapsed/refractory multiple myeloma. We want to compare how the study drug works on its own to how it works in combination with different drugs.
We are doing this study to compare the usual treatment with hormonal therapy medications to treatment with low-dose tamoxifen. We want to know which option has better outcomes for people with low-risk early-stage breast cancer.
We are doing this study to compare the standard treatments (FOLFOX or CAPOX after chemoradiation) for rectal cancer to a drug regimen called FOLFIRINOX that is given after chemoradiation. We want to know if FOLFIRINOX after chemoradiation can provide better outcomes than either of the 2 standard treatments.
We are doing this study to find out if using Radium-223 dichloride (the study drug) in combination with cabozantinib is a safe and effective treatment for advanced RCC that has spread to the bone. We want to know if this combination is potentially better than the standard treatment of cabozantinib on its own.